This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Molad, Y Articles by Amit-Vazina, M Search for Related Content PubMed PubMed Citation Articles by Molad, Y Articles by Amit-Vazina, M Social Bookmarking                   What's this?

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{

Rheumatology Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel.; ymolad{at}clalit.org.il

A Gorshtein

Rheumatology Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel; Rheumatology Service, Assaf Harofeh Hospital, Zerifin, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

A J Wysenbeek

Rheumatology Service, Assaf Harofeh Hospital, Zerifin, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

D Guedj

R Majadla

A Weinberger

Rheumatology Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel

M Amit-Vazina

Rheumatology Service, Assaf Harofeh Hospital, Zerifin, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Systemic lupus erythematosus-associated irreversible organ/system damage was previously associated with various clinical and demographic features. We analysed the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) in a cohort of 151 Israeli patients followed for a mean ( s.d.) period of 45.7 37.4 months. Mean score of SLICC/ACR DI at the first and last encounters were 0.17 64 and 1.64 2.1, respectively (P < 0.0001). Multiple logistic regression analyses disclosed a statistically significant positive correlation with corticosteroid and cyclophosphamide therapy. Hydroxychloroquine therapy was significantly associated with lower SLICC/ACR DI. Although the size of our study group did not allow us to find specific organs/systems which were associated with the protective effect of hydroxychloroquine, we suggest this is due to the antiatherogenic effects attributed to antimalarial therapy in SLE.

Key Words: damage • lupus • activity • hydroxychloroquine • antimalarial therapy

Lupus, Vol. 11, No. 6, 356-361 (2002)
DOI: 10.1191/0961203302lu203ra


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-{beta}2-glycoprotein I complexes to phospholipid bilayers Blood, September 1, 2008; 112(5): 1687 - 1695. [Abstract] [Full Text] [PDF]

				A Siso, M Ramos-Casals, A Bove, P Brito-Zeron, N Soria, S Munoz, A Testi, J Plaza, J Sentis, and A Coca Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival Lupus, April 1, 2008; 17(4): 281 - 288. [Abstract] [PDF]

				J. James, X. Kim-Howard, B. Bruner, M. Jonsson, M. McClain, M. Arbuckle, C. Walker, G. Dennis, J. Merrill, and J. Harley Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 401 - 409. [Abstract] [PDF]

				A Wozniacka, A Lesiak, J Narbutt, J Kobos, S Pavel, and A Sysa-Jedrzejowska Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus Lupus, February 1, 2007; 16(2): 89 - 94. [Abstract] [PDF]

				M Fernandez, G McGwin Jr., A M Bertoli, J Calvo-Alen, L M Vila, J D Reveille, G S Alarcon, and for the LUMINA Study Group Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL) Lupus, October 1, 2006; 15(10): 700 - 704. [PDF]

				G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus, September 1, 2006; 15(9): 577 - 583. [Abstract] [PDF]

				G. S. Alarcon, J. M. Roseman, G. McGwin Jr, A. Uribe, H. M. Bastian, B. J. Fessler, B. A. Baethge, A. W. Friedman, and J. D. Reveille Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage Rheumatology, February 1, 2004; 43(2): 202 - 205. [Abstract] [Full Text] [PDF]

				M. Soares, L Reis, J A. Papi, and C R. Cardoso Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients Lupus, October 1, 2003; 12(10): 788 - 794. [Abstract] [PDF]